TECHNOLOGYSCMP CHINA
Record Chinese biotech out-licensing meets rising US scrutiny
China's growing influence as a biotechnology innovation hub has raised strategic concerns in the United States, prompting policymakers to reassess responses. A leading analytics firm's report highlights implications for pharmaceutical supply-chain resilience, economic competitiveness, and national security.
Mentioned
Related Signal
Adjacent reporting
- Growing US reliance on Chinese biotechs prompts national security fears
- China's biotech boom alarms Western lawmakers, investors
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- China AI drug-design deals swell as US scrutiny mounts